产品
编 号：F752428
分子式：C20H12BrN5S
分子量：434.31
分子式：C20H12BrN5S
分子量：434.31
产品类型
规格
价格
是否有货
结构图
CAS No: 2414635-72-4
产品详情
生物活性：
EGFR-IN-63 is an EGFR inhibition (IC50: 0.096 μM) and it has anticancer activity in MCF-7 cells (IC50: 2.49 μM).
体外研究：
EGFR- IN-63 (2-4 hours) has superior EGFR inhibition (IC50 = 0.096 μM) compared to Gefitinib (IC50 = 0.166 μM)and anticancer activity against MCF-7 cell line (IC50 = 2.49 μM) compared to Gefitinib (IC50 = 4.972 μM). EGFR- IN-63 leads to pre G1 apoptosis with cell growth arrest at G2/M phase in MCF-7 cells after 24 h, the percentage of DNA content (41.45 %) shows increase compared to the control cells (7.1 %). EGFR- IN-63 arrest cell growth at G2/M phase and induces its apoptotic effect. The percentage of the total apoptotic cells in MCF-7 cell line increases after treatment with EGFR- IN-63(24.19 %) relative to control cells (1.47 %).
EGFR-IN-63 is an EGFR inhibition (IC50: 0.096 μM) and it has anticancer activity in MCF-7 cells (IC50: 2.49 μM).
体外研究：
EGFR- IN-63 (2-4 hours) has superior EGFR inhibition (IC50 = 0.096 μM) compared to Gefitinib (IC50 = 0.166 μM)and anticancer activity against MCF-7 cell line (IC50 = 2.49 μM) compared to Gefitinib (IC50 = 4.972 μM). EGFR- IN-63 leads to pre G1 apoptosis with cell growth arrest at G2/M phase in MCF-7 cells after 24 h, the percentage of DNA content (41.45 %) shows increase compared to the control cells (7.1 %). EGFR- IN-63 arrest cell growth at G2/M phase and induces its apoptotic effect. The percentage of the total apoptotic cells in MCF-7 cell line increases after treatment with EGFR- IN-63(24.19 %) relative to control cells (1.47 %).
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备